T2DM (Type 2 Diabetes Mellitus) Clinical Trial
Official title:
A Multi-center, phase3, Open-label Study to Evaluate the Long Term Safety and Efficacy of DWP16001 in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Gemigliptin
The subjects, having voluntarily agreed to participate in the clinical trial and provided informed consent, will undergo screening tests. During Visit 1 (Screening), subjects meeting the inclusion/exclusion criteria will go through an 8-week stabilization period. At Visit 1-1, central laboratory tests will be conducted. If the test results meet the criteria for Visit 2 (Enrollment Visit), the subject will be eligible to participate in the clinical trial. The subjects will receive the investigational drug (DWP16001 0.3 mg) once a day for 52 weeks. They will visit the clinical trial site at weeks 8, 16, 24, 38, and 52 for safety and efficacy assessments during the 52-week treatment period.
The subjects, having voluntarily agreed to participate in the clinical trial and provided informed consent, will undergo screening tests. During Visit 1 (Screening), subjects meeting the inclusion/exclusion criteria will go through an 8-week stabilization period. Throughout this period, subjects will receive concurrent administration of metformin (≥1,000 mg/day) and gemigliptin (50 mg/day), and will have a washout period for other oral antidiabetic drugs. At Visit 1-1, central laboratory tests will be conducted. If the test results meet the criteria for Visit 2 (Enrollment Visit), the subject will be eligible to participate in the clinical trial. The subjects will receive the investigational drug (DWP16001 0.3 mg) once a day for 52 weeks. They will visit the clinical trial site at weeks 8, 16, 24, 38, and 52 for safety and efficacy assessments during the 52-week treatment period. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01373814 -
Nutritional Therapy for Diabetic Cardiomyopathy
|
||
| Recruiting |
NCT05469659 -
Effect of Tofogliflozin on UACR Compared to Metformin Hydrochloride in Diabetic Kidney Disease (TRUTH-DKD)
|
Phase 2 | |
| Completed |
NCT05376930 -
Study to Evaluate the Long Term Safety and Efficacy of DWP16001 Compared to Placebo in the Treatment of T2DM.
|
Phase 3 | |
| Recruiting |
NCT04682795 -
Comparison of Safety and Efficacy of Needle-Free Injector and Insulin Pen in Patients With T2DM
|
N/A | |
| Recruiting |
NCT06350890 -
Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes
|
Phase 3 | |
| Completed |
NCT04634500 -
The Efficacy and Safety of DWP16001 in Combination With Metformin in Patients With Type 2 Diabetes.
|
Phase 3 | |
| Recruiting |
NCT03789695 -
RE-ELECT. Dabigatran vs Warfarin in AF Patients With T2DM and CKD
|
Phase 4 | |
| Completed |
NCT04632862 -
The Efficacy and Safety of DWP16001 Compared to Placebo in the Treatment of Type 2 Diabetes Mellitus.
|
Phase 3 | |
| Completed |
NCT04688359 -
Effectiveness of Nurse-coordinated Follow-up Program in Primary Care for People at Risk for T2DM
|
N/A | |
| Completed |
NCT05983289 -
Single Escalating Dose Study Of HSK7653 In Healthy Subjects
|
Phase 1 | |
| Recruiting |
NCT04272359 -
Substitution of Sulfonylureas With New Generation of Hypoglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus
|
||
| Not yet recruiting |
NCT06094491 -
Virtual Diabetes Group Visits Across Health Systems
|
N/A | |
| Completed |
NCT03467932 -
A Study to Evaluate the Efficacy and Safety of ORMD-0801 (Oral Insulin) in Patients With Type 2 Diabetes Mellitus
|
Phase 2 | |
| Completed |
NCT05376969 -
Evaluate the Long Term Safety and Efficacy of DWP16001 add-on to Metformin in Patients With T2DM Inadequately Controlled on Metformin
|
Phase 3 | |
| Completed |
NCT05279911 -
Effect of Low-level Laser Therapy on Type II Controlled Diabetic Patients After Dental Implant Insertion
|
N/A | |
| Active, not recruiting |
NCT03257449 -
Effect of Viscous Soluble Fibres on Body Weight
|
N/A | |
| Terminated |
NCT04754334 -
A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus
|
Phase 3 | |
| Not yet recruiting |
NCT06293417 -
To Assess With Ezefeno Tab. in Patients With Dyslipidemia and T2DM
|
||
| Not yet recruiting |
NCT03658031 -
Effect of Dapagliflozin on the Progression From Prediabetes to T2DM in Subjects With Myocardial Infarction
|
Phase 3 | |
| Terminated |
NCT03067480 -
Comparison of 3 Versus 6-Month Use of CGMS in Non-Insulin Using T2DM Patients
|
N/A |